Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150778 | 1.00 | EPHX2 (0.55) | EPHX2HTTDPP4EPHX1GRIN2D | |
| SCHEMBL19798760 | 0.86 | EPHX2 (0.58) | EPHX2HTTDPP4 | |
| SCHEMBL4602824 | 0.85 | DPP4 (0.50) | EPHX2HTTDPP4EPHX1GRIN2D | |
| SCHEMBL3188537 | 0.85 | GRIN2D (0.50) | EPHX2DPP4EPHX1GRIN2DGRIN3B | |
| SCHEMBL1082075 | 0.80 | EPHX2 (0.50) | EPHX2HTTDPP4EPHX1GRIN2D | |
| SCHEMBL11150971 | 0.77 | EPHX2 (0.52) | EPHX2HTTEPHX1GRIN2DGRIN3B | |
| SCHEMBL25475057 | 0.76 | GRIN2D (0.42) | EPHX2DPP4EPHX1GRIN2DGRIN3B | |
| SCHEMBL1070781 | 0.76 | GRIN2D (0.44) | EPHX2DPP4EPHX1GRIN2DGRIN3B | |
| SCHEMBL60897 | 0.76 | GRIN2D (0.48) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9298883 | 0.74 | HTT (0.58) | EPHX2HTTDPP4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0078518-B1 | A NEW P-CHLOROPHENOXYACETIC ACID DERIVATIVE, ITS METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION | SOCIEDAD ESPANOLA DE ESPECIALIDADES FARMACO-TERAPEUTICAS, S.A. (ES) | 1985-01-30 | — | — | EP | claimed |
| EP-2632929-A1 | N-HETEROCYCLIC CARBENE COMPLEXES, THEIR PREPARATION AND USE | BASF SE (DE) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012056419-A1 | N-HETEROCYCLIC CARBENE COMPLEXES, THEIR PREPARATION AND USE | BASF SE (DE) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108819-A1 | N-Heterocyclic Carbene Complexes, Their Preparation And Use | BASF SE (DE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-0078518-B1 | A NEW P-CHLOROPHENOXYACETIC ACID DERIVATIVE, ITS METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION | SOCIEDAD ESPANOLA DE ESPECIALIDADES FARMACO-TERAPEUTICAS, S.A. (ES) | 1985-01-30 | — | — | EP | disclosed |
| EP-0029658-A1 | Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | EPHX2 1794/4885HTT 3/4885DPP4 1045/4885 |
| US-20120108819-A1 | N-Heterocyclic Carbene Complexes, Their Preparation And Use | CYCS, CYC1, CBR1 | EPHX2 329/4885HTT 257/4885DPP4 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.